Levocetirizine Biogaran

Levocetirizine, the active ingredient in Levocetirizine Biogaran, is an antihistamine presented as a tablet for oral use. It treats allergic rhinitis and chronic idiopathic urticaria in adults and children when appropriate. GNH USA supplies Levocetirizine Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levocetirizine is an antihistamine that acts on the H1‑receptor pathway to relieve allergy‑related symptoms.

Allergic rhinitis: reduces sneezing, nasal itching, and rhinorrhea. Chronic idiopathic urticaria: diminishes wheal formation and itching. Seasonal allergic rhinitis: controls intermittent nasal congestion and discharge.

Levocetirizine is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Drowsiness: mild to moderate sleepiness. - Headache: transient cranial discomfort. - Dry mouth: reduced salivation. - Fatigue: general tiredness. - Nausea: mild gastrointestinal upset. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, or throat. - Severe rash: including Stevens‑Johnson syndrome. - Anaphylaxis: life‑threatening allergic reaction. - Thrombocytopenia: low platelet count. - Hepatotoxicity: abnormal liver function tests. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy, consider the following safety points.

Pregnancy: consult a healthcare professional as safety data are limited. Breastfeeding: discuss potential risks with a physician. Renal impairment: dose may need adjustment in severe cases. Elderly patients: monitor for increased sedation or confusion. Concomitant CNS depressants: may enhance drowsiness. Store at room temperature: keep in the original pack, protect from moisture.

Levocetirizine may interact with other medicines; monitor as indicated.

Major Interactions (Avoid): - Alcohol: additive sedative effect. - Strong CYP3A4 inhibitors: may raise levocetirizine plasma levels. - Monoamine oxidase inhibitors: risk of enhanced antihistaminic effects.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): increased drowsiness. - Anticholinergic agents: heightened dry‑mouth sensation. - Theophylline: possible alteration of drug metabolism.